Abstract
Objective: Clinicians often need to evaluate the treatment response of an individual person and to know that observed change is true improvement or worsening beyond usual week-to-week changes. This paper gives clinicians tools to evaluate individual changes on the MATRICS Consensus Cognitive Battery (MCCB). We compare three different approaches: a descriptive analysis of MCCB test-retest performance with no intervention, a reliable change index (RCI) approach controlling for average practice effects, and a regression approach. Method: Data were gathered as part of the MATRICS PASS study (Nuechterlein et al., 2008). A total of 159 people with schizophrenia completed the MCCB at baseline and 4. weeks later. Data were analyzed using an RCI and a regression formula establishing confidence intervals. Results: The RCI and regression approaches agree within one point when baseline values are close to the sample mean. However, the regression approach offers more accurate limits for expected change at the tails of the distribution of baseline scores. Conclusions: Although both approaches have their merits, the regression approach provides the most accurate measure of significant change across the full range of scores. As the RCI does not account for regression to the mean and has confidence limits that remain constant across baseline scores, the RCI approach effectively gives narrower confidence limits around an inaccurately predicted average change value. Further, despite the high test-retest reliability of the MCCB, a change in an individual's score must be relatively large to be confident that it is beyond normal month-to-month variation.
Original language | English |
---|---|
Pages (from-to) | 182-187 |
Number of pages | 6 |
Journal | Schizophrenia Research |
Volume | 159 |
Issue number | 1 |
DOIs | |
State | Published - 1 Oct 2014 |
Externally published | Yes |
Bibliographical note
Publisher Copyright:© 2014 Elsevier B.V.
Funding
Mr. Gray reports no support from commercial interests and has no competing interests. Dr. McMahon has been a consultant for Amgen, Inc. within the past 36 months. Dr. Green has been a consultant to AbbVie, Biogen, DSP, and Roche, and he is on the scientific advisory board of Mnemosyne. He has received research funds from Amgen. Inc. Dr. Seidman reports no support from commercial interests. He receives research support from the Massachusetts Department of Mental Health as Principal Investigator (SCDMH82101008006), from years has received investigator-initiated research funding support from the Department of Veteran's Affair, Feinstein Institute for Medical Research, GlaxoSmithKline, National Institute of Mental Health, Novartis, Psychogenics, Research Foundation for Mental Hygiene, Inc., and the Singapore National Medical Research Council. He currently or in the past 3 years has received honoraria, served as a consultant, or advisory board member for Abbvie, Akebia, Amgen, Astellas, Asubio, AviNeuro/ChemRar, BiolineRx, Biomarin, Boehringer-Ingelheim, Eli Lilly, EnVivo, GW Pharmaceuticals, Helicon, Lundbeck, Merck, Mitsubishi, Novartis, Otsuka, Pfizer, Roche, Shire, Sunovion, Takeda, and Targacept. Dr. Keefe receives royalties from the BACS testing battery and the MATRICS Battery (BACS Symbol Coding). He is also a shareholder in NeuroCog Trials, Inc. and Sengenix. Dr. Gold has been a consultant for Amgen and Pfizer, served on an advisory board for Hoffman LaRoche, and receives royalty payments from the BACS. NIMH as principal investigator (PI) or site PI, PI of site subcontract ( 1 U01 MH081928-01A1 , 2 R01 MH065571 , 1 R21 MH091461-01A1 , 1R21 MH092840-01A1 , 1R21 MH093294-01A1 , RO1 MH092440 , R01 MH096027-01 , 1R01MH092380-01A1 , RO1 MH 101052-01 , and R01 MH103831 ), or investigator ( 1R01MH096942-01A , R01 HD067744-01A1 ), and from the Sidney R. Baer, Jr. Foundation for clinical program development. Dr. Mesholam-Gately reports no support from commercial interests, and has no competing interests. Dr. Kern is an officer for MATRICS Assessment, Inc. and receives financial compensation for his role in that non-profit organization. Dr. Nuechterlein has research grants from Janssen Scientific Affairs, Genentech, and Posit Science and has served as a consultant to Genentech and Otsuka. Dr. Richard Keefe currently or in the past 3
Funders | Funder number |
---|---|
Department of Veteran's Affair | |
Feinstein Institute for Medical Research | |
Janssen Scientific Affairs | |
Singapore National Medical Research Council | |
National Institute of Mental Health | |
National Institute of Child Health and Human Development | R01HD067744 |
Genentech | |
Novartis | |
North Carolina GlaxoSmithKline Foundation |
Keywords
- MATRICS
- MCCB
- Regression
- Reliable change
- Schizophrenia